mTOR: An attractive therapeutic target for osteosarcoma?

Oncotarget

Volumn 7, Issue 31, 2016, Pages 50805-50813

  Ding, Liu ^a   Congwei, Liu ^a   Bei, Qing ^a   Tao, Yang ^a   Ruiguo, Wang ^b   Heze, Yu ^b   Bo, Dou ^b   Zhihong, Li ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

Apoptosis; Autophagy; mTOR; Osteosarcoma; Target

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; CUCURBITACIN; CUCURBITACIN B; DACTOLISIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; OLEANOLIC ACID; RAPAMYCIN; RIDAFOROLIMUS; SAPANISERTIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER INHIBITION; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; NONHUMAN; OSTEOSARCOMA; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; BONE TUMOR; CELL ENLARGEMENT; CHEMISTRY; METABOLISM; METASTASIS; PROGNOSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BONE NEOPLASMS; CELL ENLARGEMENT; CELL PROLIFERATION; HUMANS; NEOPLASM METASTASIS; OSTEOSARCOMA; PROGNOSIS; TOR SERINE-THREONINE KINASES;

EID: 84981313869     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9305     Document Type: Review

References (85)

1. Arndt CA, Rose PS, Folpe AL, Laack NN. Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc.2012;87:475-87.
2. Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, Salduca N, Versari M, Smith KV.Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer. 2001;37:32-8.
3. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23:559-68.
4. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M,Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003;9:5442-53.
5. Allison, D.C.; Carney, S.C.; Ahlmann, E.R.; Hendifar, A.; Chawla, S.; Fedenko, A.; Angeles, C.;Menendez, L.R. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 2012,704872.
6. Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
7. Gridelli C, Maione P and Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13: 139-147,2008.
8. Mita MM and Tolcher AW. The role of mTOR inhibitors for treatment of sarcomas. Curr Oncol Rep 9: 316-322, 2007.
9. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014;4:64.
10. Zoncu, R., Efeyan, A., Sabatini, D.M., 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35.
11. Laplante,M., Sabatini, D.M., 2012. mTOR signaling in growth control and disease. Cell 149, 274-293.
12. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1:27-36.
13. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews Cancer 2002; 2: 489-501.
14. Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, Hara K, Kemp BE, Witters LA, Mimura O, Yonezawa K. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes to cells: devoted to molecular & cellular mechanisms 2003; 8: 65-79.
15. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nature reviews Molecular cell biology 2007; 8: 774-85.
16. Martinet W, De Loof H, De Meyer GRY. mTOR inhibition: A promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis. Elsevier Ltd; 2014;233:601-7.
17. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, Guan JL, Oshiro N, Mizushima N. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Molecular biology of the cell 2009; 20: 1981-91.
18. Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W. PtdIns(3,4,5) P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer discovery 2015; 5: 1194-209.
19. Liu L, Parent C a. TOR kinase complexes and cell migration. J Cell Biol. 2011;194:815-24.
20. Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle. 2011;10:2305-16.
21. Gordon IK, Ye F, Kent MS.Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res. 2008 Aug;69:1079-84.
22. Liu PY, Zhang WB, Wang J, Shen YH, Wei YY.Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway inosteosarcoma stem cells and osteosarcoma cells. Zhonghua Zhong Liu Za Zhi. 2013 Mar;35:175-80.
23. Zhou R, Zhang Z, Zhao L, Jia C, Xu S, Mai Q, Lu M, Huang M, Wang L, Wang X, Jin D, Bai X. Inhibition of mTOR signaling by oleanolic acid contributes to its antitumor activity in osteosarcoma cells.J Orthop Res. 2011 Jun;29:846-52.
24. Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G, Gao Q.Lupeol Induces Apoptosis and Cell Cycle Arrest of Human Osteosarcoma Cells Through PI3K/AKT/mTORPathway. Technol Cancer Res Treat. 2015 Oct 6. [Epub ahead of print].
25. Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F, Yu P.Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. Tumour Biol. 2015 Dec;36:9873-83.
26. Song R, Tian K, Wang W, Wang L.P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway. Int J Surg. 2015 Aug;20:80-7.
27. Li G, Cai M, Fu D, Chen K, Sun M, Cai Z, Cheng B.Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem. 2012;30:1481-90.
28. Geng YD, Yang L, Zhang C, Kong LY.Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells. Food Chem Toxicol. 2014 Nov;73:7-16.
29. Ying H, Wang Z, Zhang Y, Yang TY, Ding ZH, Liu SY, Shao J, Liu Y, Fan XB.Capsaicin induces apoptosis in human osteosarcoma cells through AMPK-dependent and AMPK-independent signaling pathways. Mol Cell Biochem. 2013 Dec;384:229-37.
30. Liu WN, Lin JH, Cheng YR, Zhang L, Huang J, Wu ZY, Wang FS, Xu SG, Lin WP, Lan WB, Yang GX.FIM-A, a phosphorus-containing sirolimus, inhibits the angiogenesis and proliferation of osteosarcomas. Oncol Res. 2013;20:319-26.
31. Lin S, Shao NN, Fan L, Ma XC, Pu FF, Shao ZW.Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR. J Huazhong Univ Sci Technolog Med Sci. 2014 Dec;34:889-95.
32. Yang J, Cheng D, Zhou S, Zhu B, Hu T, Yang Q.Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma. Int J Mol Sci. 2015 Dec 2;16:28635-46.
33. Wan X, Mendoza A, Khanna C, Helman LJ.Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005 Mar 15;65:2406-11.
34. Mu X, Isaac C, Schott T, Huard J, Weiss K.Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells. Sarcoma. 2013;2013:480713.
35. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415-33.
36. Lekstan A, Lampe P, Lewin-Kowalik J, Olakowski M, Jablonska B, Labuzek K, Jedrzejowska-Szypulka H, Olakowska E, Gorka D, Filip I, Dranka-Bojarowska D. Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma. J Physiol Pharmacol. 2012;63:589-99.
37. Mu X, Brynien D, Weiss KR. The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcomacells. Biomed Res Int. 2015;2015:290368.
38. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy.Cancer. 1994;73:2013-2026.
39. Boehm I.Apoptosis in physiological and pathological skin: implications for therapy. Curr Mol Med. 2006 Jun;6:375-94.
40. Wang X, Lai P, Zhang Z, Huang M, Wang L, Yin M, Jin D, Zhou R, Bai X.Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. Oncol Rep. 2014 Jul;32:382-8.
41. Yao C, Wei JJ, Wang ZY, Ding HM, Li D, Yan SC, Yang YJ, Gu ZP.Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy? Cell Biochem Biophys. 2013 Mar;65:217-27. doi: 10.1007/s12013-012-9423-5.
42. Miwa S, Sugimoto N, Yamamoto N, Shirai T, Nishida H, Hayashi K, Kimura H, Takeuchi A, Igarashi K, Yachie A, Tsuchiya H.Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-B and MAPK pathways. Anticancer Res. 2012 Sep;32:3643-9.
43. Zhou R, Zhang Z, Zhao L, Jia C, Xu S, Mai Q, Lu M, Huang M, Wang L, Wang X, Jin D, Bai X.Inhibition of mTOR signaling by oleanolic acid contributes to its antitumor activity in osteosarcoma cells.J Orthop Res. 2011 Jun;29:846-52. doi: 10.1002/jor.21311. Epub 2011 Jan 18.
44. Gazitt Y, Kolaparthi V, Moncada K, Thomas C, Freeman J.Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol. 2009 Feb;34:551-61.
45. Liang D, Yang M, Guo B, Yang L, Cao J, Zhang X.HIF-1 induced by-elemene protects human osteosarcoma cells from undergoing apoptosis. J Cancer Res Clin Oncol. 2012 Nov;138:1865-77.
46. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069-1075.
47. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy.2012;8:445-544.
48. Burada F, Nicoli ER, Ciurea ME, Uscatu DC, Ioana M, Gheonea DI.Autophagy in colorectal cancer: An important switch from physiology to pathology.World J Gastrointest Oncol. 2015 Nov 15;7:271-84.
49. Lindqvist LM, Simon AK, Baehrecke EH.Current questions and possible controversies in autophagy. Cell Death Discov. 2015;1.
50. Akin D, Wang SK, Habibzadegah-Tari P, Law B, Ostrov D, Li M, Yin XM, Kim JS, Horenstein N, Dunn WA Jr. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcomatumors. Autophagy. 2014;10:2021-35.
51. Mori M, Hitora T, Nakamura O, Yamagami Y, Horie R, Nishimura H, Yamamoto T. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells. Int J Oncol. 2015 Jan;46:47-54.
52. Pan J, Chen B, Su CH, Zhao R, Xu ZX, Sun L, Lee MH, Yeung SC. Autophagy induced by farnesyltransferase inhibitors in cancer cells. Cancer Biol Ther. 2008 Oct;7:1679-84.
53. Xie Z, Xie Y, Xu Y, Zhou H, Xu W, Dong Q. Bafilomycin A1 inhibits autophagy and induces apoptosis in MG63 osteosarcoma cells. Mol Med Rep. 2014 Aug;10:1103-7.
54. Xie ZG, Xie Y, Dong QR. Inhibition of the mammalian target of rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells. Oncol Lett. 2013 Nov;6:1465-1469.
55. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing the complexity of DNAdamage response pathways to improve cancer treatment outcomes.Oncogene. 2010;29:6085-6098.
56. Gewirtz DA. Autophagy as a mechanism of radiation sensitization in breast tumor cells. Autophagy. 2007;3:249-250.
57. John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, Thomas T, and Thomas TJ, et al. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res. 2008;68:7855-7863.
58. Buytaert E, Callewaert G, Vandenheede JR, Agostinis P. Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy. 2006;2:238-240.
59. Zhu X, Du X, Deng X, Yi H, Cui S, Liu W, Shen A, Cui Z. C6 ceramide sensitizes pemetrexed-induced apoptosis and cytotoxicity in osteosarcoma cells. Biochem Biophys Res Commun. 2014 Sep 12;452:72-8.
60. Wang X, Lai P, Zhang Z, Huang M, Wang L, Yin M, Jin D, Zhou R, Bai X.Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. Oncol Rep. 2014 Jul;32:382-8.
61. Zhao S, Lu N, Chai Y, Yu X. Rapamycin inhibits tumor growth of human osteosarcomas. J BUON. 2015 Mar-Apr;20:588-94.
62. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW,Haluska FG, Demetri GD.Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012 Jan 1;30:78-84.
63. Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz GK.MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and softtissue sarcoma. Mol Cancer Ther. 2015 Feb;14:395-406.
64. Jiang H, Zeng Z.Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma. Biochem Biophys Res Commun. 2015 Dec 4;468:255-61.
65. Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, Mönkkönen J, Rédini F, Heymann D.Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010 Dec 15;70:10329-39.
66. Lee DH, Thoennissen NH, Goff C, Iwanski GB, Forscher C, Doan NB, Said JW, Koeffler HP.Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett. 2011 Jul 28;306:161-70.
67. Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S,Alberghini M, Picci P, Aglietta M, Grignani G.The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcomapreclinical models. Clin Cancer Res. 2013 Apr 15;19:2117-31.
68. Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, Franssen GM, Flucke UE, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT.Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. Int J Cancer. 2014 Dec 15;135:2770-82.
69. Lee DH, Qi J, Bradner JE, Said JW, Doan NB, Forscher C, Yang H, Koeffler HP.Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer. 2015 May 1;136:2055-64.
70. Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015 Jan;16:98-107.
71. Horie R, Nakamura O, Yamagami Y, Mori M, Nishimura H, Fukuoka N, Yamamoto T.Apoptosis and antitumor effects induced by the combination of an mTOR inhibitor and an autophagy inhibitor in human osteosarcoma MG63 cells. Int J Oncol. 2016 Jan;48:37-44.
72. Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Rédini F, Ory B, Heymann D. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett. 2014 Mar 28;344:291-8.
73. Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma. Cancer Biol Ther. 2015;16:602-9.
74. Amaravadi RK, Thompson CB. The roles of therapyinduced autophagy and necrosis in cancer treatment.Clin Cancer Res. 2007;13:7271-7279.
75. Bishop SC, Burlison JA, Blagg BS. Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets. 2007;7:369-388.
76. Zuehlke A, Johnson JL. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers. 2010;93:211-217.
77. Mori M, Hitora T, Nakamura O, Yamagami Y, Horie R, Nishimura H, Yamamoto T.Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells. Int J Oncol. 2015 Jan;46:47-54.
78. Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, Doyle LA, Chen H, Blaney SM.Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar;62:440-4.
79. Goudarzi KM, Nistér M, Lindström MS. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels. Cancer Biol Ther. 2014;15:1499-514.
80. Miliani de Marval PL.Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2011; 2:234-8. doi: 10.18632/oncotarget.228.
81. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009; 16:369-77.
82. Zhou X., Liao JM., Liao WJ. Lu H. Scission of the p53-MDM2 loop by ribosomal proteins. Genes & Cancer 2012; 3:298-310.
83. Avitabile D., Bailey B. Cottage CT., Sundararaman B., Joyo A., McGregor M., Gude N., Truffa S., Zarrabi A., Konstandin M, Khan M, Mohsin S, Völkers M, et al. Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin. Proc Natl Acad Sci U S A 2011; 108:6145-50.
84. Sun XX., Dai MS., Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 2007; 282:8052-9.
85. D. Sun XX., Dai MS., Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 2008; 283:12387-92.